



AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A phosphatidyl-L-serine sodium salt ~~composition~~ having a fatty acid composition identical to that of soybean lecithin and a degree of peroxidation of less than 5 produced by reacting phosphatides of formula (II):




wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine in the presence of an effective amount of phospholipase D with transphosphatidylase activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from soybean, and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is ~~at least~~over 95% pure.

2. **(Currently Amended)** A phosphatidyl-L-serine sodium salt ~~composition~~ having a fatty acid composition identical to that of egg lecithin and a degree of peroxidation of less than 5 produced by reacting phosphatides of formula (II):




wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine in the presence of an effective amount of phospholipase D with transphosphatidylase activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from egg, and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is ~~at least~~over 95% pure.

3. **(Currently Amended)** A phosphatidyl-L-serine sodium salt ~~composition~~ having a fatty acid composition identical to that of soybean lecithin and a degree of peroxidation of less than 5 produced by reacting phosphatides of formula (II):




wherein R is diacylglycerol and R_2 is $\text{CH}_2 - \text{CH}_2 - \text{NH}_2$ or $\text{CH}_2 - \text{CH}_2 - \text{N}(\text{CH}_3)_3$, with serine in the presence of an effective amount of phospholipase D with transphosphatidylase activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction, and wherein said phosphatides of formula II are obtained from soybean and wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2, and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is at least over 95% pure.

4. **(Currently Amended)** A phosphatidyl-L-serine sodium salt ~~composition~~ having a fatty acid composition identical to that of egg lecithin and a degree of peroxidation of less than 5 produced by reacting phosphatides of formula (II):




wherein R is diacylglycerol and R_2 is $\text{CH}_2 - \text{CH}_2 - \text{NH}_2$ or $\text{CH}_2 - \text{CH}_2 - \text{N}(\text{CH}_3)_3$, with serine in the presence of an effective amount of phospholipase D with transphosphatidylase activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction and wherein said phosphatides of formula II are obtained from soybean and wherein said phospholipase D is purified by eluting on an anionic cationic exchange resin at a pH of 6.2, and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is at least over 95% pure.

5. **(Currently Amended)** A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a phosphatidyl-L-serine sodium salt of formula (I)



wherein R is diacylglycerol and R_1 is ~~an hydroxyl group~~ a hydrogen,


made by the process of reacting a phosphatide of formula (II):



wherein R is diacylglycerol and R_2 is $\text{CH}_2 - \text{CH}_2 - \text{NH}_2$ or $\text{CH}_2 - \text{CH}_2 - \text{N}(\text{CH}_3)_3$, with serine in the presence of an effective amount of phospholipase D with transphosphatidylase activity produced


from a *Streptomyces hachijoense* strain to catalyze the reaction to obtain said phosphatide according to formula (I) , and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is ~~at least~~over 95% pure.

6. **(Currently Amended)** A cosmetic composition comprising a pharmaceutically acceptable carrier and a phosphatidyl-L-serine sodium salt of formula (I)




wherein R is diacylglycerol and R₁ is ~~an hydroxyl group~~ a hydrogen,

made by the process of reacting a phosphatide of formula (II):




wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced from a *Streptomyces hachijoense* strain to catalyze the reaction to obtain said phosphatide according to formula (I) , and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is ~~at least~~over 95% pure.

7. **(Currently Amended)** A food and dietary supplement comprising a carrier and a phosphatidyl-L-serine sodium salt of formula (I)



wherein R is diacylglycerol and R₁ is ~~an hydroxyl group~~ a hydrogen,

made by the process of reacting a phosphatide of formula (II):



wherein R is diacylglycerol and R₂ is CH₂ – CH₂ – NH₂ or CH₂ – CH₂ – N(CH₃)₃, with serine in the presence of an effective amount of phospholipase D with transphosphatidylation activity produced

from a *Streptomyces hachijoense* strain to catalyze the reaction to obtain said phosphatide according to formula (I) , and wherein said reaction is conducted under nitrogen, and wherein said phosphatidyl-L-serine sodium salt is ~~at least~~over 95% pure.

8. **(Previously Presented)** The food and dietary supplement according to claim 7, wherein the *Streptomyces hachijoense* strain is ATCC 19769.

9. **(Currently Amended)** A pharmaceutical composition capable of being administered orally comprising a pharmaceutically acceptable carrier and the phosphatidyl-L-serine sodium salt ~~composition~~ according to claim 1, 2, 3 or 4.

10. **(Currently Amended)** A cosmetic composition for topical application to the skin comprising a pharmaceutically acceptable carrier and the phosphatidyl-L-serine sodium salt according to claim 1, 2, 3 or 4.

11. **(Currently Amended)** A food and dietary supplement capable of being administered orally comprising a carrier and the phosphatidyl-L-serine sodium salt according to claim 1, 2, 3 or 4.

12-14. **(Canceled)**

15. **(Previously Presented)** The pharmaceutical composition according to claim 5 in the form of a capsule, tablet or granule.

16. **(Previously Presented)** The cosmetic composition according to claim 6 in the form of a cream or a gel.

17. **(Original)** A food and dietary supplement according to claim 7 in the form of a capsule, tablet or granule.

18. **(Original)** A food and dietary supplement according to claim 11 in the form of a capsule, tablet or granule.

19. **(Original)** The food and dietary supplement according to claim 8, wherein the phosphatide of formula (II) is selected from the group consisting of purified soybean lecithin and crude soybean lecithin.

20. **(Canceled)**

21. **(Currently Amended)** The phosphatidyl-L-serine ~~composition~~ according to claim 1 or 2, wherein the formula II phosphatide reactant is phosphatidylcholine, and wherein said phosphatidylcholine reactant is completely converted to product phosphatidyl-L-serine.

22. **(Canceled)**